ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $67,963 | -10.3% | 3,388 | +26.2% | 0.00% | 0.0% |
| Q2 2023 | $75,744 | +74.6% | 2,685 | +6.5% | 0.00% | +100.0% |
| Q1 2023 | $43,378 | -23.8% | 2,522 | -10.8% | 0.00% | -33.3% |
| Q4 2022 | $56,956 | -7.0% | 2,828 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $61,254 | -4.3% | 2,828 | +24.1% | 0.00% | 0.0% |
| Q2 2022 | $64,012 | -39.1% | 2,278 | 0.0% | 0.00% | -25.0% |
| Q1 2022 | $105,107 | -86.7% | 2,278 | -75.8% | 0.00% | -63.6% |
| Q4 2021 | $791,593 | +26.1% | 9,417 | 0.0% | 0.01% | +22.2% |
| Q3 2021 | $627,549 | +38.6% | 9,417 | +10.7% | 0.01% | +50.0% |
| Q2 2021 | $452,679 | +26.0% | 8,509 | +2.8% | 0.01% | +20.0% |
| Q1 2021 | $359,226 | -16.5% | 8,279 | 0.0% | 0.01% | -16.7% |
| Q4 2020 | $430,011 | +275.3% | 8,279 | +136.2% | 0.01% | +200.0% |
| Q3 2020 | $114,578 | -31.9% | 3,505 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $168,310 | – | 3,505 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |